Works matching IS 14712407 AND DT 2024 AND VI 24 AND IP 1

Results: 1377
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12395-3
    By:
    • Wang, Beihe;
    • Pan, Jian;
    • Zhang, Tingwei;
    • Ni, Xudong;
    • Wei, Yu;
    • Li, Xiaomeng;
    • Fang, Bangwei;
    • Hu, Xiaoxin;
    • Gan, Hualei;
    • Wu, Junlong;
    • Wang, Hongkai;
    • Ye, Dingwei;
    • Zhu, Yao
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17

    heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12179-9
    By:
    • Kuemmel, Sherko;
    • Harper-Wynne, Catherine;
    • Park, Yeon Hee;
    • Franke, Fábio;
    • de Laurentiis, Michelino;
    • Schumacher-Wulf, Eva;
    • Eiger, Daniel;
    • Heeson, Sarah;
    • Cardona, Andrés;
    • Özyilkan, Özgür;
    • Morales-Vàsquez, Flavia;
    • Metcalfe, Ciara;
    • Hafner, Marc;
    • Restuccia, Eleonora;
    • O'Shaughnessy, Joyce
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12336-0
    By:
    • Janssen, J. C.;
    • van Dijk, B.;
    • de Joode, K.;
    • Aarts, M. J. B.;
    • van den Berkmortel, F. W. P. J.;
    • Blank, C. U.;
    • Boers-Sonderen, M. J.;
    • van den Eertwegh, A. J. M.;
    • de Groot, J. W. B.;
    • Jalving, M.;
    • de Jonge, M. J. A.;
    • Joosse, A.;
    • Kapiteijn, E.;
    • Kamphuis-Huismans, A. M.;
    • Naipal, K. A. T.;
    • Piersma, D.;
    • Rikhof, B.;
    • Westgeest, H. M.;
    • Vreugdenhil, G.;
    • Oomen-de Hoop, E.
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50